2025 Q3 -tulosraportti
15 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
477
Myynti
Määrä
27 607
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 299 | NON | NON | ||
| 2 474 | NON | NON | ||
| 2 623 | DDB | NON | ||
| 377 | DDB | NON | ||
| 35 | NON | AVA |
Ylin
10,45VWAP
Alin
9,42VaihtoMäärä
0,6 56 723
VWAP
Ylin
10,45Alin
9,42VaihtoMäärä
0,6 56 723
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 13 913 | 5 951 | +7 962 | 0 |
| Nordnet Bank AB | 37 883 | 36 270 | +1 613 | 24 826 |
| Svenska Handelsbanken AB | 500 | 170 | +330 | 20 |
| Avanza Bank AB | 953 | 2 605 | −1 652 | 0 |
| SSW Market Making GmbH | 3 474 | 11 727 | −8 253 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 3 474 | 11 727 | −8 253 | 0 |
| Avanza Bank AB | 953 | 2 605 | −1 652 | 0 |
| Svenska Handelsbanken AB | 500 | 170 | +330 | 20 |
| Nordnet Bank AB | 37 883 | 36 270 | +1 613 | 24 826 |
| Danske Bank A/S | 13 913 | 5 951 | +7 962 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenRelax, an order that's on the sell side 😂 28k shares
·4 t sittenWait, let me just get my wallet.. 😂😅
·5 t sittenCurasight is hopefully NOT an obvious acquisition for Curium..! I do NOT believe that Curium is the right party to acquire Curasight and bring it to market. And I hope NOT that management goes down that path, as we would then not maximize the value of Curasight. • Curium is a global radiopharma producer specializing in the production and distribution of medical isotopes, especially ¹⁷⁷Lu, ¹³¹I and other beta-/alpha emitters. • They supply radiopharmaceuticals for clinical studies and commercial use, but they are primarily a supplier/producer, not a traditional commercial partner for specific therapeutic programs. • Curium has previously supplied isotopes for Approved therapies, e.g.: - Xofigo® (Ra 223): they supplied Ra 223 to Bayer. - 177Lu DOTATATE (Lutathera®): supplier to Advanced Accelerator Applications/Novartis. They have competencies in supply chain and GMP production, but no history of independent marketing of radiopharma drugs. Conclusion: Curium ensures a stable supply of isotopes, critical for uTREAT. But they lack go-to-market experience with niche-oncological radioligands. Their role best suits as a strategic supplier and possible minority investor, not as a main actor for global commercialization. To maximize the commercialization potential, Curasight should consider a partnership with larger pharma (Novartis/Bayer), possibly in combination with Curium for supply chain. • Novartis: strong track record with Lutathera® and the PSMA program. • Bayer: has experience with Ra 223 (Xofigo®). There are no signs that it will be Curium, as they entered into milestone payments of up to 500 mill kr. Management has made some good capital injection agreements for the ongoing operations in 2026.- ·9 t sitten · MuokattuCurium has reportedly raised 7 billion dollars. Payout is expected in Q1 2026. It is the largest transaction in nuclear medicine globally. The money will be used for: • Development • Strategic partnerships • Acquisitions The recapitalization will accelerate Curium's strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients worldwide. Could Curasight be an obvious acquisition? https://www.curiumpharma.com/2025/11/20/capvest-recapitalizes-curium/?fbclid=IwZnRzaAOuB4NleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEe6PJqYmCtL5rjWz-QsZQj4XANTics8-8KIQ7oS6ryV3aqWGg_Kcz1kaJWMAY_aem_O97TqV0BiVXGfDgy1bprew
·10 t sittenIt looks like we'll have a cautious day without much trading volume. Under 4000 units so far..
·9 t sittenRecruitment in the EMA system means that the first suitable patient has been found. So the question is what their strategy is for communication.·8 t sittenGood to know. So FPD could be very close now. I don't think they give it the same day the patient has agreed to the trial. There might be other examinations and scans in the normal course that first need to be completed. I still think the patient follows the normal treatment as backup. Knowing that the response time for a biopsy is up to 10 working days. So there can certainly be blockades that put FPD on hold until there is 100% clarity about the patient's illness.- ·21 t sitten · MuokattuThis is how much the shares have been diluted since the start in 2020 Date Total # shares Dilution % 22-10-2020 17.126.340 0,00 % 07-10-2021 19.893.891(TO1) 13,91 % 10-12-2024 21.148.880(TO2) 2,21 % 21-05-2025 44.886.242 52,88 % 02-06-2025 45.864.010 2,13 % 18-06-2025 45.867.511(TO3) 0,01 % 12-12-2025 47.922.841 4,29 % We hope that it holds until The Main Event 🚀 (it's a poor editor..! 👀)·9 t sitten · MuokattuThere is actually a potential dilution ahead if Fenja exercises its conversion right in connection with the loan of 25 mill (at a price of 9,975) Fenja, conversion (max) 50.429.107 4,97% Let's hope that Fenja finds it attractive to exercise the conversion right 😉 That gives a total accumulated dilution of 66,20 % since start.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
15 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenRelax, an order that's on the sell side 😂 28k shares·4 t sittenWait, let me just get my wallet.. 😂😅
- ·5 t sittenCurasight is hopefully NOT an obvious acquisition for Curium..! I do NOT believe that Curium is the right party to acquire Curasight and bring it to market. And I hope NOT that management goes down that path, as we would then not maximize the value of Curasight. • Curium is a global radiopharma producer specializing in the production and distribution of medical isotopes, especially ¹⁷⁷Lu, ¹³¹I and other beta-/alpha emitters. • They supply radiopharmaceuticals for clinical studies and commercial use, but they are primarily a supplier/producer, not a traditional commercial partner for specific therapeutic programs. • Curium has previously supplied isotopes for Approved therapies, e.g.: - Xofigo® (Ra 223): they supplied Ra 223 to Bayer. - 177Lu DOTATATE (Lutathera®): supplier to Advanced Accelerator Applications/Novartis. They have competencies in supply chain and GMP production, but no history of independent marketing of radiopharma drugs. Conclusion: Curium ensures a stable supply of isotopes, critical for uTREAT. But they lack go-to-market experience with niche-oncological radioligands. Their role best suits as a strategic supplier and possible minority investor, not as a main actor for global commercialization. To maximize the commercialization potential, Curasight should consider a partnership with larger pharma (Novartis/Bayer), possibly in combination with Curium for supply chain. • Novartis: strong track record with Lutathera® and the PSMA program. • Bayer: has experience with Ra 223 (Xofigo®). There are no signs that it will be Curium, as they entered into milestone payments of up to 500 mill kr. Management has made some good capital injection agreements for the ongoing operations in 2026.
- ·9 t sitten · MuokattuCurium has reportedly raised 7 billion dollars. Payout is expected in Q1 2026. It is the largest transaction in nuclear medicine globally. The money will be used for: • Development • Strategic partnerships • Acquisitions The recapitalization will accelerate Curium's strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients worldwide. Could Curasight be an obvious acquisition? https://www.curiumpharma.com/2025/11/20/capvest-recapitalizes-curium/?fbclid=IwZnRzaAOuB4NleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEe6PJqYmCtL5rjWz-QsZQj4XANTics8-8KIQ7oS6ryV3aqWGg_Kcz1kaJWMAY_aem_O97TqV0BiVXGfDgy1bprew
- ·10 t sittenIt looks like we'll have a cautious day without much trading volume. Under 4000 units so far..·9 t sittenRecruitment in the EMA system means that the first suitable patient has been found. So the question is what their strategy is for communication.·8 t sittenGood to know. So FPD could be very close now. I don't think they give it the same day the patient has agreed to the trial. There might be other examinations and scans in the normal course that first need to be completed. I still think the patient follows the normal treatment as backup. Knowing that the response time for a biopsy is up to 10 working days. So there can certainly be blockades that put FPD on hold until there is 100% clarity about the patient's illness.
- ·21 t sitten · MuokattuThis is how much the shares have been diluted since the start in 2020 Date Total # shares Dilution % 22-10-2020 17.126.340 0,00 % 07-10-2021 19.893.891(TO1) 13,91 % 10-12-2024 21.148.880(TO2) 2,21 % 21-05-2025 44.886.242 52,88 % 02-06-2025 45.864.010 2,13 % 18-06-2025 45.867.511(TO3) 0,01 % 12-12-2025 47.922.841 4,29 % We hope that it holds until The Main Event 🚀 (it's a poor editor..! 👀)·9 t sitten · MuokattuThere is actually a potential dilution ahead if Fenja exercises its conversion right in connection with the loan of 25 mill (at a price of 9,975) Fenja, conversion (max) 50.429.107 4,97% Let's hope that Fenja finds it attractive to exercise the conversion right 😉 That gives a total accumulated dilution of 66,20 % since start.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
477
Myynti
Määrä
27 607
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 299 | NON | NON | ||
| 2 474 | NON | NON | ||
| 2 623 | DDB | NON | ||
| 377 | DDB | NON | ||
| 35 | NON | AVA |
Ylin
10,45VWAP
Alin
9,42VaihtoMäärä
0,6 56 723
VWAP
Ylin
10,45Alin
9,42VaihtoMäärä
0,6 56 723
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 13 913 | 5 951 | +7 962 | 0 |
| Nordnet Bank AB | 37 883 | 36 270 | +1 613 | 24 826 |
| Svenska Handelsbanken AB | 500 | 170 | +330 | 20 |
| Avanza Bank AB | 953 | 2 605 | −1 652 | 0 |
| SSW Market Making GmbH | 3 474 | 11 727 | −8 253 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 3 474 | 11 727 | −8 253 | 0 |
| Avanza Bank AB | 953 | 2 605 | −1 652 | 0 |
| Svenska Handelsbanken AB | 500 | 170 | +330 | 20 |
| Nordnet Bank AB | 37 883 | 36 270 | +1 613 | 24 826 |
| Danske Bank A/S | 13 913 | 5 951 | +7 962 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
15 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenRelax, an order that's on the sell side 😂 28k shares·4 t sittenWait, let me just get my wallet.. 😂😅
- ·5 t sittenCurasight is hopefully NOT an obvious acquisition for Curium..! I do NOT believe that Curium is the right party to acquire Curasight and bring it to market. And I hope NOT that management goes down that path, as we would then not maximize the value of Curasight. • Curium is a global radiopharma producer specializing in the production and distribution of medical isotopes, especially ¹⁷⁷Lu, ¹³¹I and other beta-/alpha emitters. • They supply radiopharmaceuticals for clinical studies and commercial use, but they are primarily a supplier/producer, not a traditional commercial partner for specific therapeutic programs. • Curium has previously supplied isotopes for Approved therapies, e.g.: - Xofigo® (Ra 223): they supplied Ra 223 to Bayer. - 177Lu DOTATATE (Lutathera®): supplier to Advanced Accelerator Applications/Novartis. They have competencies in supply chain and GMP production, but no history of independent marketing of radiopharma drugs. Conclusion: Curium ensures a stable supply of isotopes, critical for uTREAT. But they lack go-to-market experience with niche-oncological radioligands. Their role best suits as a strategic supplier and possible minority investor, not as a main actor for global commercialization. To maximize the commercialization potential, Curasight should consider a partnership with larger pharma (Novartis/Bayer), possibly in combination with Curium for supply chain. • Novartis: strong track record with Lutathera® and the PSMA program. • Bayer: has experience with Ra 223 (Xofigo®). There are no signs that it will be Curium, as they entered into milestone payments of up to 500 mill kr. Management has made some good capital injection agreements for the ongoing operations in 2026.
- ·9 t sitten · MuokattuCurium has reportedly raised 7 billion dollars. Payout is expected in Q1 2026. It is the largest transaction in nuclear medicine globally. The money will be used for: • Development • Strategic partnerships • Acquisitions The recapitalization will accelerate Curium's strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients worldwide. Could Curasight be an obvious acquisition? https://www.curiumpharma.com/2025/11/20/capvest-recapitalizes-curium/?fbclid=IwZnRzaAOuB4NleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEe6PJqYmCtL5rjWz-QsZQj4XANTics8-8KIQ7oS6ryV3aqWGg_Kcz1kaJWMAY_aem_O97TqV0BiVXGfDgy1bprew
- ·10 t sittenIt looks like we'll have a cautious day without much trading volume. Under 4000 units so far..·9 t sittenRecruitment in the EMA system means that the first suitable patient has been found. So the question is what their strategy is for communication.·8 t sittenGood to know. So FPD could be very close now. I don't think they give it the same day the patient has agreed to the trial. There might be other examinations and scans in the normal course that first need to be completed. I still think the patient follows the normal treatment as backup. Knowing that the response time for a biopsy is up to 10 working days. So there can certainly be blockades that put FPD on hold until there is 100% clarity about the patient's illness.
- ·21 t sitten · MuokattuThis is how much the shares have been diluted since the start in 2020 Date Total # shares Dilution % 22-10-2020 17.126.340 0,00 % 07-10-2021 19.893.891(TO1) 13,91 % 10-12-2024 21.148.880(TO2) 2,21 % 21-05-2025 44.886.242 52,88 % 02-06-2025 45.864.010 2,13 % 18-06-2025 45.867.511(TO3) 0,01 % 12-12-2025 47.922.841 4,29 % We hope that it holds until The Main Event 🚀 (it's a poor editor..! 👀)·9 t sitten · MuokattuThere is actually a potential dilution ahead if Fenja exercises its conversion right in connection with the loan of 25 mill (at a price of 9,975) Fenja, conversion (max) 50.429.107 4,97% Let's hope that Fenja finds it attractive to exercise the conversion right 😉 That gives a total accumulated dilution of 66,20 % since start.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
477
Myynti
Määrä
27 607
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 299 | NON | NON | ||
| 2 474 | NON | NON | ||
| 2 623 | DDB | NON | ||
| 377 | DDB | NON | ||
| 35 | NON | AVA |
Ylin
10,45VWAP
Alin
9,42VaihtoMäärä
0,6 56 723
VWAP
Ylin
10,45Alin
9,42VaihtoMäärä
0,6 56 723
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 13 913 | 5 951 | +7 962 | 0 |
| Nordnet Bank AB | 37 883 | 36 270 | +1 613 | 24 826 |
| Svenska Handelsbanken AB | 500 | 170 | +330 | 20 |
| Avanza Bank AB | 953 | 2 605 | −1 652 | 0 |
| SSW Market Making GmbH | 3 474 | 11 727 | −8 253 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 3 474 | 11 727 | −8 253 | 0 |
| Avanza Bank AB | 953 | 2 605 | −1 652 | 0 |
| Svenska Handelsbanken AB | 500 | 170 | +330 | 20 |
| Nordnet Bank AB | 37 883 | 36 270 | +1 613 | 24 826 |
| Danske Bank A/S | 13 913 | 5 951 | +7 962 | 0 |